However, no tumor uptake was detected in HER2-negative patients, indicating the specificity of Lu-177-trastuzumab for HER2-positive cancer diagnosis and probably becoming targeted radionuclide therapy for HER2-positive cancer shortly. Here, ERBB2 is linked to neoplasm.